IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.36 Million Stock Position in Guardant Health, Inc. $GH

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 403.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,324 shares of the company’s stock after purchasing an additional 36,320 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Guardant Health were worth $2,359,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its position in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares in the last quarter. American Century Companies Inc. increased its position in shares of Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock worth $4,439,000 after purchasing an additional 282 shares in the last quarter. IFP Advisors Inc increased its position in shares of Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Guardant Health by 0.9% during the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock worth $2,177,000 after purchasing an additional 469 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Guardant Health by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock worth $112,000 after purchasing an additional 537 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Price Performance

Guardant Health stock opened at $69.58 on Wednesday. The company’s 50 day simple moving average is $62.70 and its 200 day simple moving average is $52.34. Guardant Health, Inc. has a fifty-two week low of $21.28 and a fifty-two week high of $73.31. The firm has a market capitalization of $8.68 billion, a price-to-earnings ratio of -20.77 and a beta of 1.53.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same period in the previous year, the business earned ($0.84) EPS. The firm’s revenue was up 31.0% compared to the same quarter last year. As a group, analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on GH shares. William Blair reissued an “outperform” rating on shares of Guardant Health in a report on Thursday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a report on Thursday, September 25th. Finally, BTIG Research set a $80.00 price objective on shares of Guardant Health in a report on Thursday, September 25th. Twenty-three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $67.29.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director owned 851 shares of the company’s stock, valued at $46,090.16. This trade represents a 71.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of Guardant Health stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. The trade was a 12.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 302,691 shares of company stock worth $17,984,628 in the last three months. 6.10% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.